氯沙坦代谢物血清浓度与衰弱前期老年人躯体功能改善相关:一项初步研究
该探索性初步研究将25例70–90岁衰弱前期老年人随机分配至安慰剂对照或氯沙坦治疗组(从25 mg/日开始,每8周递增),疗程共6个月。血清氯沙坦及EXP3179浓度与衰弱评分负相关,EXP3179和EXP3174每增加1个标准差,平均膝关节力量分别增加0.0035 N和0.0027 N。
要点
- EXP3179和EXP3174每增1个标准差,平均膝关节力量分别增0.0035 N和0.0027 N。
核心结论
- 在衰弱前期老年人中,氯沙坦治疗与衰弱 odds 和衰弱评分降低相关,且血清氯沙坦及EXP3179浓度与衰弱评分负相关。
- EXP3179和EXP3174血清浓度升高与平均膝关节力量增加相关。
- 该研究为探索性初步研究,结果需进一步验证。
研究设计与样本
- 探索性初步研究,纳入25例70–90岁衰弱前期老年人。
- 参与者随机分配至安慰剂对照组或氯沙坦治疗组,氯沙坦从25 mg/日开始、每8周递增,总疗程6个月。
主要发现
- 衰弱评分与血清氯沙坦及EXP3179浓度呈负相关。
- EXP3179每增加1个标准差(0.0011 ng/μL),平均膝关节力量增加0.0035 N(95%CI:0.0019–0.0051,p<0.001)。
关键数值与推荐
- EXP3179每增加1个标准差(0.0011 ng/μL),平均膝关节力量增加0.0035 N(95%CI:0.0019–0.0051,p<0.001)。
临床怎么用
- 对衰弱前期老年人使用氯沙坦时需监测疲劳、高钾血症和低血压等不良反应。
- 血清氯沙坦代谢物浓度与衰弱评分及膝关节力量相关,提示其可能作为药效监测指标,但尚需验证。
局限性
- 本研究为探索性初步研究,样本量小(N=25),结果需在更大样本中验证。
- 原文未报告盲法、分配隐藏、脱落率及统计效能等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Losartan is an oral antihypertensive agent that is rapidly metabolized to EXP3174 (angiotensin-subtype-1-receptor blocker) and EXP3179 (peroxisome proliferator-activated receptor gamma [PPARγ] agonist), which was shown in animal studies to reduce inflammation, enhance mitochondrial energetics, and improve muscle repair and physical performance. We conducted an exploratory pilot study evaluating losartan treatment in prefrail older adults (age 70-90 years, N = 25). Participants were randomized to control (placebo) or treatment (daily oral losartan beginning at 25 mg per day and increasing every 8 weeks) for a total of 6 months. Fatigue, hyperkalemia, and hypotension were the most observed side effects of losartan treatment. Participants in the losartan group had an estimated 89% lower odds of frailty (95% confidence interval [CI]: 18% to 99% lower odds, p = .03), with a 0.3-point lower frailty score than the placebo group (95% CI: 0.01-0.5 lower odds, p = .04). Frailty score was also negatively associated with serum losartan and EXP3179 concentrations. For every one standard deviation increase in EXP3179 (ie, 0.0011 ng/μL, based on sample values above detection limit) and EXP3174 (ie, 0.27 ng/μL, based on sample values above detection limit), there was a 0.0035 N (95% CI: 0.0019-0.0051, p < .001) and a 0.0027 N (95% CI: 0.00054-0.0043, p = .007) increase in average knee strength, respectively.
引用
- Lee JL, Zhang C, Westbrook R, et al. Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults. J Gerontol A Biol Sci Med Sci. 2022. PMID: 35511890. doi:10.1093/gerona/glac102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。